Xagenic Raises $11.8M to Commercialize POC Dx Platform | GenomeWeb

NEW YORK (GenomeWeb) – Molecular diagnostics Firm Xagenic today announced that it has raised C$15 million ($11.8 million) in new financing that it hopes will accelerate its efforts to develop and commercialize its point-of-care diagnostic platform.

Headquartered in Toronto, Xagenic has been developing a platform it calls the Xagenic X1 based on a core technology that was originally developed by researchers at the University of Toronto.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.